menu
    • menu
    [{"orgOrder":0,"company":"University of North Carolina","sponsor":"OpenBiome | Crohn's and Colitis Foundation | The Broad Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Formic Acid","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of North Carolina \/ OpenBiome | Crohn's and Colitis Foundation | The Broad Foundation","highestDevelopmentStatusID":"7","companyTruncated":"University of North Carolina \/ OpenBiome | Crohn's and Colitis Foundation | The Broad Foundation"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Formic Acid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Formic Acid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Jean-Pierre Routy","sponsor":"St. Joseph's Health Care London","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Formic Acid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Jean-Pierre Routy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jean-Pierre Routy \/ St. Joseph's Health Care London","highestDevelopmentStatusID":"8","companyTruncated":"Jean-Pierre Routy \/ St. Joseph's Health Care London"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Formic Acid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Health \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for 06460_FLUKA

    Menu

    06460_FLUKA

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jean-Pierre Routy

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Jean-Pierre Routy

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Formic Acid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : St. Joseph's Health Care London

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fecal Microbiota Translantation (FMT) to Reduce Inflammation in PLWH: The Gutsy Pilot Study

                            Details : FMT is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 01, 2023

                            Lead Product(s) : Formic Acid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : St. Joseph's Health Care London

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rambam Health Care Campus

                            Israel arrow
                            OTS 2025
                            Not Confirmed

                            Rambam Health Care Campus

                            Israel arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Formic Acid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae

                            Details : FMT is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Carbapenem-Resistant Enterobacteriaceae Infections.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 10, 2021

                            Lead Product(s) : Formic Acid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rambam Health Care Campus

                            Israel arrow
                            OTS 2025
                            Not Confirmed

                            Rambam Health Care Campus

                            Israel arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Formic Acid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fecal Microbiota Transplantation for Carbapenem-resistant Enterobacteriaceae

                            Details : FMT is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Carbapenem-Resistant Enterobacteriaceae Infections.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 31, 2019

                            Lead Product(s) : Formic Acid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            University of North Carolina

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            University of North Carolina

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Formic Acid

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I/ Phase II

                            Sponsor : OpenBiome | Crohn's and Colitis Foundation | The Broad Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchit...

                            Details : FMT is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pouchitis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 25, 2016

                            Lead Product(s) : Formic Acid

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : OpenBiome | Crohn's and Colitis Foundation | The Broad Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Endeavor Health

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Endeavor Health

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Formic Acid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI

                            Details : FMT is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Clostridium Infections.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 02, 2014

                            Lead Product(s) : Formic Acid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth